Key points from article :
Turn Biotechnologies has acquired the global rights for new technology that reprograms cells to undo many of the effects of aging.
Licensed its epigenetic reprogramming of age (ERA™) technology.
“ERA technology is an extremely powerful platform and can be used to treat a variety of diseases,” - Anja Krammer, Turn CEO.
Uses messenger RNA (mRNA) to deliver transcription factors to the cells’ epigenome.
Transcription factors effectively revitalize the epigenome, restoring the cells’ ability to behave more youthfully.
“We will be able to turn back the clock on cellular vitality to heal or regenerate damaged tissue,” - Jay Sarkar, Chief technology officer.
An advantage of mRNA is that it is safe because it never enters the cell nucleus.
The use of mRNA heralds a revolution in the development of therapeutics safer, faster, more efficient, and tuneable to patient need.
Research by the Stanford School of Medicine published in the Journal Nature.
